SHMT2: Validation as a therapeutic target for ATC and study of its molecular mechanism

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400080643

Enrollment

Unknown

Registered

2024-02-04

Start date

2024-02-04

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

undifferentiated carcinoma of thyroid gland

Interventions

Experimental group:None

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1, gender is not limited; 2. Preoperative FNA and postoperative pathological type were thyroid undifferentiated carcinoma; 3, can comply with the research visit plan and other program requirements; 4. If you voluntarily participate in and sign the informed consent, you can participate in this study after signing the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: Other pathologic types of thyroid cancer were identified

Design outcomes

Primary

Measure	Time frame
Staining effect of pathological section;	—

Countries

China

Contacts

Public ContactBing Liu

The Second Affiliated Hospital of Harbin Medical University

olwl@163.com+86 139 3630 2101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026